Abstract
Acute cardiac allograft rejection is still a major complication after heart transplantation. Acute rejection usually responds to conventional immunosuppressions, however, the nonspecific nature of the immunosuppression and the toxicities of the drugs can be life threatening and may compromise the recipients quality of life. In addition, cardiac allograft arteriosclerosis or chronic rejection limits the long-term survival of recipients. Such conditions cannot be prevented with conventional therapies. To overcome acute and chronic rejection of cardiac allograft as well as ischemia / reperfusion injury associated with organ preservation many novel approaches have been proposed. Gene transfection of the donor organ during organ preservation is an attractive method, because the transfected genes would not affect recipients and treatment could be delivered specifically to the site of inflammation. This method could be useful to prevent graft failure without systemic adverse effects. Here we shall review current advances in gene therapies to prevent and treat organ failure of transplanted allografts.
Keywords: acute rejection, chronic rejection, gene therapy, graft vasculopathy, heart transplantation, immunosuppression, ischemia/reperfusion injury, tolerance
Current Gene Therapy
Title: Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Volume: 4 Issue: 2
Author(s): Mitsuaki Isobe, Hisanori Kosuge, Noritaka Koga, Hideki Futamatsu and Jun-ichi Suzuki
Affiliation:
Keywords: acute rejection, chronic rejection, gene therapy, graft vasculopathy, heart transplantation, immunosuppression, ischemia/reperfusion injury, tolerance
Abstract: Acute cardiac allograft rejection is still a major complication after heart transplantation. Acute rejection usually responds to conventional immunosuppressions, however, the nonspecific nature of the immunosuppression and the toxicities of the drugs can be life threatening and may compromise the recipients quality of life. In addition, cardiac allograft arteriosclerosis or chronic rejection limits the long-term survival of recipients. Such conditions cannot be prevented with conventional therapies. To overcome acute and chronic rejection of cardiac allograft as well as ischemia / reperfusion injury associated with organ preservation many novel approaches have been proposed. Gene transfection of the donor organ during organ preservation is an attractive method, because the transfected genes would not affect recipients and treatment could be delivered specifically to the site of inflammation. This method could be useful to prevent graft failure without systemic adverse effects. Here we shall review current advances in gene therapies to prevent and treat organ failure of transplanted allografts.
Export Options
About this article
Cite this article as:
Isobe Mitsuaki, Kosuge Hisanori, Koga Noritaka, Futamatsu Hideki and Suzuki Jun-ichi, Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis, Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346507
DOI https://dx.doi.org/10.2174/1566523043346507 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and The Cross-talk Between Them
Current Drug Targets Proteasome as an Emerging Therapeutic Target in Cancer
Current Pharmaceutical Design Human Carbonyl Reductases
Current Drug Metabolism Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Spinal Cord Ischemia/Injury
Current Pharmaceutical Design The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes
Recent Patents on Cardiovascular Drug Discovery Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Chemical and Pharmacological Aspects of Heteroaryl-Nitrones
Current Medicinal Chemistry